论文信息 - The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate. - 字舞流文

The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate.

C. Shun | N. Chou | N. Chi | I. Wu | S. Huang | Y. Chen | H. Yu | C. Tsao | W. Ko | S. Wang | C. Wang | Ys. Chen

[1] Maryl R. Johnson,et al. Management of allosensitized cardiac transplant candidates. , 2009, Transplantation reviews.

[2] N. Chou,et al. Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus. , 2008, Transplantation proceedings.

[3] S. Chu,et al. Effect of plasmapheresis for acute humoral rejection after heart transplantation. , 2006, Transplantation proceedings.

[4] N. Chou,et al. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients. , 2006, Transplantation Proceedings.

[5] S. Nissen,et al. New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, Md. , 2006, Circulation.

[6] E. Tuzcu,et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.

[7] Jon Kobashigawa,et al. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? , 2000, Current controlled trials in cardiovascular medicine.

[8] I. Loeb,et al. [Cyclosporine A]. , 2005, Revue de stomatologie et de chirurgie maxillo-faciale.

[9] P. Halloran. drug therapy Immunosuppressive Drugs for Kidney Transplantation , 2004 .